Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890714) titled 'A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daiichi Sankyo
Condition:
Urothelial Cancer
Non-small Cell Lung Cancer
Intervention:
Drug: Dato-DXd
Drug: Enfortumab Vedotin (EV)
Drug: Pembrolizumab
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 16, 2026
Target Sample Size: 268
Countries of Recruitment:
Taiwan
To know more, visit https:/...